— The Allen Institute appointed Chris Beaudoin as its new chief operations officer. Beaudoin was beforehand chief working officer at Swedish, a Seattle-area healthcare system affiliated with Windfall.
Previous to becoming a member of Swedish, Beaudoin spent a decade at Renton-based Windfall, working in pharmacy providers and operations earlier than turning into a part of the company enterprise staff tasked with associate integration. He served because the chief transition officer at Windfall for its $20 billion merger with St. Joseph Well being in 2017.
Beaudoin additionally labored six years at GlaxoSmithKline as an govt gross sales rep. He’ll begin the brand new job in mid-November. The Allen Institute, a Seattle-based nonprofit analysis establishment based by the late Paul Allen, appointed a brand new CEO and president, Rui Costa, final December.
Different key personnel adjustments throughout the Pacific Northwest tech business:
- Rick Pittenger is now chief know-how officer of Seattle well being tech startup DexCare. Pittinger was beforehand chief know-how officer at analytics firm Lucid, which was acquired by digital market analysis firm Cint final 12 months for about $1.1 billion. Pittenger remained at Cint as CTO for a couple of 12 months earlier than becoming a member of DexCare in November.
- Laura Cooper, beforehand senior director of company communications at Adaptive Biotechnologies, joined Day One Biopharmaceuticals as head of company communications.
- Rippl Care, a just lately launched Seattle psychological well being startup geared for seniors, employed Jesse Schlueter as chief individuals officer. Schlueter was beforehand senior VP of human sources, expertise and folks operations at Nordstrom.
- Jamie Cohen, chief monetary officer of Vacasa, joined the board of administrators at pet sitting firm Rover.
- Michael Goldstein was employed as president and chief medical officer of Aurion Biotech, which raised $120 million in April to advance its experimental remedy for a typical corneal situation.
- Richard Graydon, beforehand senior director of scientific growth at Johnson & Johnson, is now interim chief medical officer of Atossa Therapeutics.